Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Plain-language summary
This Phase 2 trial is testing Biospecimen Collection, Bone Marrow Aspiration, and other medications for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 7 US locations across multiple states.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
- May require specific number of prior treatments
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Biospecimen Collection (PROCEDURE): Undergo blood sample collection | Bone Marrow Aspiration (PROCEDURE): Undergo bone marrow aspiration and biopsy | Bone Marrow Biopsy (PROCEDURE): Undergo bone marrow aspiration and biopsy | Chimeric Antigen Receptor T-Cell Therapy (BIOLOGICAL): Undergo standard of care CAR-T therapy | Computed Tomography (PROCEDURE): Undergo CT or PET/CT | Golcadomide (DRUG): Given PO | Leukapheresis (PROCEDURE): Undergo leukapheresis | Positron Emission Tomography (PROCEDURE): Undergo PET/CT | Rituximab (BIOLOGICAL): Given IV
- Drugs / treatments
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Golcadomide, Leukapheresis, Positron Emission Tomography, Rituximab
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details